Humacyte, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Humacyte, Inc. (HUMA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $4.10 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $4.10.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $4.21.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $4.25.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $4.71.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $4.10 10-Q · filed 2026-08-12 |
| 2026-03-31 | $4.21 10-Q · filed 2026-05-13 |
| 2025-12-31 | $4.25 10-K · filed 2026-03-27 |
| 2025-09-30 | $4.71 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.69 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.86 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.96 10-K · filed 2025-03-31 |
| 2024-09-30 | $4.97 10-Q · filed 2024-11-08 |
| 2024-06-30 | $4.89 10-Q · filed 2024-08-13 |
| 2024-03-31 | $4.64 10-Q · filed 2024-05-13 |
| 2023-12-31 | $4.64 10-K · filed 2024-03-28 |
| 2023-09-30 | $5.90 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.91 10-Q · filed 2023-08-14 |
| 2023-03-31 | $5.91 10-Q · filed 2023-05-12 |
| 2022-12-31 | $5.90 10-K · filed 2023-03-24 |
| 2022-09-30 | $7.20 10-Q · filed 2022-11-10 |
| 2022-06-30 | $7.29 10-Q · filed 2022-08-12 |
| 2022-03-31 | $7.40 10-Q · filed 2022-05-13 |
| 2021-12-31 | $7.48 10-K · filed 2022-03-29 |
| 2021-09-30 | $7.33 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |